Can activation of NRF2 be a strategy against COVID-19?
A Cuadrado, M Pajares, C Benito… - Trends in …, 2020 - cell.com
Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of
a dysregulated host response, followed by damage to alveolar cells and lung fibrosis …
a dysregulated host response, followed by damage to alveolar cells and lung fibrosis …
The duration of infectiousness of individuals infected with SARS-CoV-2
KA Walsh, S Spillane, L Comber, K Cardwell… - Journal of Infection, 2020 - Elsevier
Objectives To summarise the evidence on the duration of infectiousness of individuals in
whom SARS-CoV-2 ribonucleic acid is detected. Methods A rapid review was undertaken in …
whom SARS-CoV-2 ribonucleic acid is detected. Methods A rapid review was undertaken in …
Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19
F D'Agnillo, KA Walters, Y Xiao, ZM Sheng… - Science translational …, 2021 - science.org
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is characterized by respiratory distress, multiorgan …
coronavirus 2 (SARS-CoV-2), is characterized by respiratory distress, multiorgan …
Tocilizumab in hospitalized patients with severe Covid-19 pneumonia
IO Rosas, N Bräu, M Waters, RC Go… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an …
AS Soin, K Kumar, NS Choudhary… - The Lancet …, 2021 - thelancet.com
Background Global randomised controlled trials of the anti-IL-6 receptor antibody
tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but …
tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but …
ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida
E Oliveira, A Parikh, A Lopez-Ruiz, M Carrilo… - PloS one, 2021 - journals.plos.org
Background Observational studies have consistently described poor clinical outcomes and
increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who …
increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who …
Obesity and COVID-19: molecular mechanisms linking both pandemics
The coronavirus disease 2019 COVID-19 pandemic is rapidly spreading worldwide and is
becoming a major public health crisis. Increasing evidence demonstrates a strong …
becoming a major public health crisis. Increasing evidence demonstrates a strong …
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients …
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients …
[HTML][HTML] COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis
Abstract Infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2) is associated with onset of neurological and psychiatric symptoms during and after the …
2) is associated with onset of neurological and psychiatric symptoms during and after the …
COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness
F Du, B Liu, S Zhang - Journal of thrombosis and thrombolysis, 2021 - Springer
The novel coronavirus disease (COVID-19) has become a universally prevalent infectious
disease. The causative virus of COVID-19 is severe acute respiratory syndrome coronavirus …
disease. The causative virus of COVID-19 is severe acute respiratory syndrome coronavirus …